The case, which occurred in a Phase 1 trial of Moderna’s jab for the Epstein-Barr virus, will only add to the concerns around mRNA biotechnology and heart issues, particularly myocarditis.

Investigators for Moderna today halted an early-stage clinical trial for its mRNA Epstein-Barr virus vaccine in adolescents after a participant in the trial developed a suspected case of myocarditis.

The case “necessitates an immediate suspension of all dosing for ALL adolescents,” an investigator at the company that is supervising the trial for Moderna wrote, adding, “Please confirm understanding and receipt of this urgent communication.”

The trial subjects should continue to be monitored for safety, the investigator wrote. About 150 adolescents are in the trial, along with 272 people aged 18-30.

A person not employed by Moderna, which makes the Spikevax Covid vaccine, provided the email to Unreported Truths.

Posted in

Iron Will

Leave a Comment

You must be logged in to post a comment.